Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Preoperative Endocrine Therapy"'
Autor:
Isabel Grote, Stephan Bartels, Leonie Kandt, Laura Bollmann, Henriette Christgen, Malte Gronewold, Mieke Raap, Ulrich Lehmann, Oleg Gluz, Ulrike Nitz, Sherko Kuemmel, Christine zuEulenburg, Michael Braun, Bahriye Aktas, Eva‐Maria Grischke, Claudia Schumacher, Kerstin Luedtke‐Heckenkamp, Ronald Kates, Rachel Wuerstlein, Monika Graeser, Nadia Harbeck, Matthias Christgen, Hans Kreipe
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8581-8594 (2021)
Abstract Background Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying pri
Externí odkaz:
https://doaj.org/article/2c544d649b024c5bbd721b91d7f7c740
Autor:
Henriette Christgen, Laura Bollmann, Mieke Raap, Rachel Wuerstlein, Bahriye Aktas, Ronald E. Kates, Ulrike Nitz, Ulrich Lehmann, Monika Graeser, Oleg Gluz, Michael Braun, Hans Kreipe, Sherko Kuemmel, Claudia Schumacher, Matthias Christgen, Malte Gronewold, Stephan Bartels, Nadia Harbeck, Eva-Maria Grischke, Christine Eulenburg, Isabel Grote, Kerstin Luedtke-Heckenkamp, Leonie Kandt
Publikováno v:
Cancer Medicine, Vol 10, Iss 23, Pp 8581-8594 (2021)
Cancer Medicine
Cancer Medicine
Background Whereas the genomic landscape of endocrine‐resistant breast cancer has been intensely characterized in previously treated cases with local or distant recurrence, comparably little is known about genomic alterations conveying primary non
Autor:
Tomoharu Sugie, Yasuo Ohashi, Takanori Ishida, Hironori Haga, Akira Shimizu, Masahiro Takada, Nobuaki Sato, Shigehira Saji, Hiroshi Ishiguro, Kenjiro Aogi, Hiroji Iwata, Takayuki Kinoshita, Masahiro Kitada, Toshiaki Saeki, Yuichiro Kai, Yasuyuki Sato, Kenjiro Jimbo, Norikazu Masuda, Shigeru Imoto, Yoshinori Ito, Takafumi Ikeda, Hirofumi Mukai, Masakazu Toi, Takayuki Ueno, Shinji Ohno
Publikováno v:
The Lancet Oncology. 22:74-84
Oral fluoropyrimidines, such as S-1, have been shown to have a role in controlling disease progression in metastatic breast cancer. We examined adjuvant treatment with S-1 in patients with oestrogen receptor (ER)-positive and HER2-negative primary br
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yasushi Ito, Norihiko Shiiya, Kei Koizumi, Keigo Goto, Hiroki Mori, Toru Watanabe, Ryoichi Matsunuma, Hiroyuki Ogura, Noriko Sawai, Shoko Maruyama, Yasuo Hozumi
Publikováno v:
Breast Cancer. 27:819-827
Luminal B-like breast cancer is sensitive to both chemotherapy and endocrine therapy. We aimed to assess the safety and efficacy of concomitant chemotherapy and endocrine therapy compared with chemotherapy alone in the preoperative setting in luminal
Autor:
S A Tyulyandin, Y.I. Kochetkova, A.V. Petrovsky, O.V. Krohina, M.A. Frolova, M.B. Stenina, Y.V. Vishnevskaya
Publikováno v:
Practical oncology. 20:326-335
Autor:
Icro Meattini, Elżbieta Senkus, Orit Kaidar-Person, Aleksandra Łacko, Maria João Cardoso, Philip Poortmans
Publikováno v:
Cancer treatment reviews
Introduction of sentinel lymph node biopsy, initially in clinically node-negative and subsequently in patients presenting with involved axilla and downstaged by primary systemic therapy, allowed for significant decrease in morbidity compared to axill
Autor:
Montserrat Muñoz, Aleix Prat
Publikováno v:
The Lancet Oncology
[ ]substantial heterogeneity exists in hormone receptor-positive, HER2-negative disease regarding patient prognosis and treatment benefit 1 To date, tools available before any systemic intervention has taken place, such as the Ki67 proliferation-rela
Autor:
Jeffrey T. Chang, Jason I. Griffiths, Issam Makhoul, Cynthia X. Ma, Kevin Kalinsky, Aditya Bardia, Patrick A. Cosgrove, Frederick R. Adler, Kari B. Wisinski, Meghna S. Trivedi, Laura Spring, Andrea Bild, Priyanka Sharma, Adam L. Cohen, Ruth O'Regan, Anne O'Dea, Jinfeng Chen, Qamar J. Khan
Combining cyclin-dependent kinase (CDK) inhibitors with endocrine therapy improves outcomes for metastatic estrogen receptor positive (ER+), HER2 negative, breast cancer patients. However, the value of this combination in potentially curable earlier
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7370bfef295c534119aa3676f360e4c
https://doi.org/10.1101/2021.01.19.427299
https://doi.org/10.1101/2021.01.19.427299
Autor:
Nadia Harbeck
Publikováno v:
Current Opinion in Obstetrics & Gynecology
PURPOSE OF REVIEW: The present review summarizes recent original publications addressing the topic of risk-adapted adjuvant therapy in early breast cancer (EBC). As neoadjuvant therapy has become a standard for triple negative and HER2+ EBC, it focus